MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021
August 03 2021 - 9:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a Fireside Chat in the BTIG
Virtual Biotechnology Conference 2021 on Tuesday, August 10, 2021
at 12:30 PM (ET).
BTIG hosted events are intended for prospective
and existing BTIG clients only. To listen to the live event, please
contact your BTIG representative with interest.
About MannKind
CorporationMannKind Corporation (Nasdaq: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra-rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. Afrezza is also available by prescription in Brazil
where it is commercialized by the Company’s partner Biomm SA.
MannKind was established in 1991, and is headquartered in Westlake
Village, Calif., with a manufacturing and R&D facility in
Danbury, Conn. The Company also employs field sales and medical
representatives across the U.S. Please visit www.mannkindcorp.com
to learn more.
MANNKIND CONTACT:Rose Alinaya,
Investor Relations Phone: (818) 661-5000 Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024